Efficacy of Variable‐Particle Hyaluronic Acid Dermal Fillers in Patients with Skin of Color: A Randomized, Evaluator‐Blinded Comparative Trial

C. Burgess,Susan C. Taylor,V. Callender
DOI: https://doi.org/10.1111/j.1524-4725.2010.01552.x
2010-04-20
Abstract:BACKGROUND Nonanimal stabilized hyaluronic acid (HA) dermal fillers are used to treat moderate to severe facial wrinkles and folds. Trials of HA generally have included few patients with pigmented skin. OBJECTIVE To compare the efficacy and tolerability of small‐gel‐particle (SGP) and large‐gel‐particle (LGP) HA in correcting nasolabial folds in patients with Fitzpatrick skin types IV to VI. METHODS AND MATERIALS One hundred fifty patients with Fitzpatrick skin types IV to VI received one treatment with SGP and LGP HA. Investigators and patients evaluated efficacy using palpability assessments and change from baseline Wrinkle Severity Rating Scale (WSRS) score at 2, 6, 12, and 24 weeks. RESULTS According to investigator evaluation, LGP HA reduced wrinkles by at least 1 WSRS grade in 95% of patients at 6 weeks and in 92% at 12 weeks, and SGP HA reduced wrinkles by at least 1 WSRS grade in 96% of patients at 6 weeks and in 93% at 12 weeks. Both fillers endured for at least 24 weeks. Patient assessments were 86% and 85% for LGP HA at 6 and 12 weeks, respectively, and 88% and 86% for SGP HA, respectively. Both fillers were well tolerated. Pigmentation changes occurred in 6% and 9% of patients treated with LGP and SGP HA, respectively. There were 17 cases of hyperpigmentation. Pigmentation changes occurred in 7% of patients with skin type IV, 13% with skin type V, and 13% with skin type VI. Most were mild or moderate and resolved within 12 weeks, except for three patients with postinflammatory hyperpigmentation. There were three reported mass formations, two of which were infectious in nature. CONCLUSION Variable‐particle HA fillers are effective and well tolerated in patients with skin of color. Medicis Aesthetics Inc. (Scottsdale, AZ) sponsored this study and provided the Restylane and Perlane used. Study funding was also provided to the authors and investigators, as was the contribution of medical writer Barbara Huber, BA, a consultant and writer for Premier Healthcare Resource, Inc., Morristown, NJ.
Medicine
What problem does this paper attempt to address?